Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 375, Issue 6, pp 377–382

Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John’s wort

  • Ute Gödtel-Armbrust
  • Annegret Metzger
  • Ulrike Kroll
  • Olaf Kelber
  • Leszek Wojnowski
Original Article

Abstract

St. John’s wort (SJW, Hypericum perforatum) is a well-tolerated herbal medicine widely used for the treatment of mild and moderate depressions. In the last 5 years, SJW has been implicated in drug interactions, which are largely mediated by the induction of the drug metabolizing enzymes, especially CYP3A4. There is still some controversy regarding the exact mechanism of induction and the identity of the SJW constituents involved. We investigated in LS174T cells the induction of CYP3A4 by ten SJW extracts, six commercial preparations, and the purified SJW constituent hyperforin. The content of hyperforin among the commercial preparations of SJW varied 62-fold (range 0.49–30.57 mg/dose). The CYP3A4 induction was mediated by PXR, but not by CAR. The magnitude of the induction correlated statistically significantly with the content of hyperforin in commercial SJW preparations (R = 0.87, p = 0.004) and in dry extracts (R = 0.65, p = 0.03), but not with their content of flavonoids or hypericin. Most of the CYP3A4 induction response occurred in the hyperforin range encountered in the blood of patients treated with SJW preparations. A temperature-induced decrease in the hyperforin content of a selected dry SJW extract abolished the induction of CYP3A4. In conclusion, commercial SJW preparations still exhibit an enormous variability in CYP3A4 induction, which is mediated by hyperforin and PXR. SJW preparations with lower hyperforin content should reduce the frequency of clinical interactions involving this herbal drug.

Keywords

St. John’s wort Hyperforin Induction CYP3A4 CYP3A PXR CAR Drug interactions 

References

  1. Bertilsson G, Berkenstam A, Blomquist P (2001) Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem Biophys Res Commun 280:139–144PubMedCrossRefGoogle Scholar
  2. Bros M, Ross XL, Pautz A, Reske-Kunz AB, Ross R (2003) The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol 171:1825–1834PubMedGoogle Scholar
  3. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P et al (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:24280–24288PubMedCrossRefGoogle Scholar
  4. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954–1965PubMedCrossRefGoogle Scholar
  5. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598PubMedCrossRefGoogle Scholar
  6. Gaedcke F (1997) Herstellung, Qualität, Analytik und Anwendung von Johanniskraut-Extrakten. Z Arzn Gew pfl 2:63–72Google Scholar
  7. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587PubMedCrossRefGoogle Scholar
  8. Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J (2006) Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 72:685–690PubMedCrossRefGoogle Scholar
  9. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349–356PubMedCrossRefGoogle Scholar
  10. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L et al (2001) Natural protein variants of pregnane × receptor with altered transactivation activity toward cyp3a4. Drug Metab Dispos 29:1454–1459PubMedGoogle Scholar
  11. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH et al (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82PubMedCrossRefGoogle Scholar
  12. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY et al (2004) Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512–518PubMedCrossRefGoogle Scholar
  13. Linde K, Mulrow CD, Berner M, Egger M (2005) St John’s wort for depression. Cochrane Database Syst Rev CD000448Google Scholar
  14. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502PubMedCrossRefGoogle Scholar
  15. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G et al (2006) The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62:29–36PubMedCrossRefGoogle Scholar
  16. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88–95PubMedGoogle Scholar
  17. Pal D, Mitra AK (2006) MDR- and CYP3A4-mediated drug–herbal interactions. Life Sci 78:2131–2145PubMedCrossRefGoogle Scholar
  18. Patel J, Buddha B, Dey S, Pal D, Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262–277PubMedCrossRefGoogle Scholar
  19. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) Indinavir concentrations and St John’s wort. Lancet 355:547PubMedCrossRefGoogle Scholar
  20. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G (2000) Acute heart transplant rejection due to Saint John’s wort. Lancet 355:548–549PubMedCrossRefGoogle Scholar
  21. Sueyoshi T, Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123–143PubMedCrossRefGoogle Scholar
  22. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD (1976) Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12:180–191PubMedGoogle Scholar
  23. Wurglics M, Schubert-Zsilavecz M (2006) Hypericum perforatum: a ‘modern’ herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45:449–468PubMedCrossRefGoogle Scholar
  24. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M (2001) Comparison of German St. John’s wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash) 41:560–566Google Scholar
  25. Zanoli P (2004) Role of hyperforin in the pharmacological activities of St. John’s Wort. CNS Drug Rev 10:203–218PubMedCrossRefGoogle Scholar
  26. Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD (2004) Pharmacokinetic Interactions of Drugs with St John’s Wort. J Psychopharmacol 18:262–276PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Ute Gödtel-Armbrust
    • 1
  • Annegret Metzger
    • 1
  • Ulrike Kroll
    • 2
  • Olaf Kelber
    • 2
  • Leszek Wojnowski
    • 1
  1. 1.Institut für PharmakologieJohannes Gutenberg UniversitätMainzGermany
  2. 2.Wissenschaftliche AbteilungSteigerwald Arzneimittelwerk GmbHDarmstadtGermany

Personalised recommendations